Shopping Cart 0
Cart Subtotal
AED 0

EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
AED 5505

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
AED 8074

Details

MARKET OUTLOOK

Triton Market Research has estimated the Europe hyperphosphatemia drugs market to show an upward trend in terms of revenue and grow rapidly with a CAGR of 16.11% in the forecasting years 2019-2027.

France, Italy, the United Kingdom, Germany, Russia, Spain and countries in rest of Europe together form the market for hyperphosphatemia drugs in the European region.

The growing aging population and increasing osteoporosis cases in the UK are the major driving factors strengthening the demand for the hyperphosphatemia drugs market in the country. In the UK, around 3 million people are expected to be suffering from osteoporosis. Additionally, more than 230,000 fracture cases are recorded every year due to osteoporosis. A low level of estrogen in women or other hormone might significantly increase the risk of weakening the bones.

The increasing aging population in Spain is considered as the major driving factor to strengthen the demand of the hyperphosphatemia drugs market in the country. Spain accounts for a significant proportion of elderly population within Europe. By 2050, one-fourth of Spain's population is estimated to be over 100 years. The aging population can be considered as the most crucial reason for the rising prevalence of hyperphosphatemia disorders that is driving the growth of the Spain market. In cases of chronic kidney diseases and elderly people, the loss of phosphorus homeostasis due to phosphorus excretion failure causes hyperphosphatemia. And this is growing the demand for the hyperphosphatemia drugs market in the country.

COMPETITIVE OUTLOOK

The companies contending in the market are Fermenta Biotech, Ltd., Sanofi, Roche Diagnostics Corporation, Pfizer, Inc., Royal DSM N.V., Fresenius Medical Care, Sun Pharmaceutical Industries, Ltd., Cipla, AMAG Pharmaceuticals, Keryx Biopharmaceuticals, Inc., Bio-Tech Pharmacal, Ultragenyx Pharmaceutical, Inc., Johnson and Johnson, Shire, Zeria Pharmaceutical and Bruno Farmaceutici S.p.A.

READ MORE

Table Of Content

Scope

TABLE OF CONTENT

1. EUROPE HYPERPHOSPHATEMIA DRUGS MARKET-SUMMARY

2. INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER'S FIVE FORCE MODEL

2.2.1. THREAT OF NEW ENTRANTS

2.2.2. BARGAINING POWER OF BUYERS

2.2.3. BARGAINING POWER OF SUPPLIERS

2.2.4. THREAT OF SUBSTITUTE PRODUCT

2.2.5. INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. KEY BUYING OUTLOOK

2.5. KEY INSIGHTS

2.6. KEY MARKET TRENDS

2.7. GUIDELINES RELATED TO THE PHOSPHATE BINDERS

2.8. MARKET DRIVERS

2.8.1. CHRONIC DISORDERS ARE INCREASING RAPIDLY

2.8.2. INCREASE IN PUBLIC COGNIZANCE

2.8.3. INCREASE IN GERIATRIC POPULATION

2.9. MARKET RESTRAINTS

2.9.1. SIDE-EFFECTS RELATED TO THE USAGE OF HYPERPHOSPHATEMIA DRUGS

2.9.2. STRICT FOOD AND DRUG ADMINISTRATION (FDA) REGULATIONS

2.10. MARKET OPPORTUNITIES

2.10.1. RISE IN THE AGING POPULATION

2.11. MARKET CHALLENGES

2.11.1. ALTERNATIVE DIALYSIS TECHNIQUES

2.11.2. ACCESSIBILITY OF DRUGS IS LIMITED

2.11.3. NON-ADHERENCE TO TREATMENT REGIMES

3. HYPERPHOSPHATEMIA DRUGS MARKET OUTLOOK-BY DOSAGES

3.1. SOLID

3.1.1. TABLET

3.1.2. POWDER

3.2. LIQUID

3.2.1. SOLUTION

4. HYPERPHOSPHATEMIA DRUGS MARKET OUTLOOK-BY FORMULATION

4.1.1. CALCIUM-BASED PHOSPHATE BINDERS

4.1.2. ALUMINUM-BASED PHOSPHATE BINDERS

4.1.3. MAGNESIUM-BASED PHOSPHATE BINDERS

4.1.4. IRON-BASED PHOSPHATE BINDERS

4.1.5. OTHER PHOSPHATE BINDERS

5. HYPERPHOSPHATEMIA DRUGS MARKET-REGIONAL OUTLOOK

5.1. EUROPE

5.1.1. COUNTRY ANALYSIS

5.1.1.1. UNITED KINGDOM

5.1.1.2. FRANCE

5.1.1.3. GERMANY

5.1.1.4. SPAIN

5.1.1.5. ITALY

5.1.1.6. RUSSIA

5.1.1.7. REST OF EUROPE

6. COMPETITIVE LANDSCAPE

6.1. JOHNSON AND JOHNSON

6.2. ZERIA PHARMACEUTICAL

6.3. AMAG PHARMACEUTICALS

6.4. SANOFI

6.5. BRUNO FARMACEUTICI S.P.A.

6.6. ROCHE DIAGNOSTICS CORPORATION

6.7. ROYAL DSM N.V.

6.8. SHIRE

6.9. CIPLA

6.10. ULTRAGENYX PHARMACEUTICAL, INC.

6.11. FERMENTA BIOTECH, LTD.

6.12. BIOTECH PHARMACAL

6.13. SUN PHARMACEUTICAL INDUSTRIES, LTD.

6.14. KERYX BIOPHARMACEUTICALS, INC.

6.15. FRESENIUS MEDICAL CARE

6.16. PFIZER, INC.

7. METHODOLOGY & SCOPE

7.1. RESEARCH SCOPE

7.2. SOURCES OF DATA

7.3. RESEARCH METHODOLOGY

 

 

 

 

 

TABLE LIST

TABLE 1 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

TABLE 2 PHOSPHOROUS LEVELS IN SELECT FOODS

TABLE 3 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027 (USD MILLION)

TABLE 4 DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE

TABLE 5 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET COUNTRY ANALYSIS 2019-2027 (USD MILLION)

 

 

 

 

FIGURE LIST

FIGURE 1 PORTER'S FIVE FORCES MODEL OF HYPERPHOSPHATEMIA DRUGS MARKET

FIGURE 2 IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2017

FIGURE 3 RATE OF ADHERENCE TO PHOSPHATE BINDERS

FIGURE 4 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN CALCIUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 5 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 6 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 7 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN IRON-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 8 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN OTHER PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 9 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET SHARE 2018 & 2027 (%)

FIGURE 10 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 11 UNITED KINGDOM HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 12 FRANCE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 13 GERMANY HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 14 SPAIN HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 15 ITALY HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 16 RUSSIA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 17 REST OF EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)


List Of Figure

FIGURE LIST

FIGURE 1 PORTER'S FIVE FORCES MODEL OF HYPERPHOSPHATEMIA DRUGS MARKET

FIGURE 2 IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2017

FIGURE 3 RATE OF ADHERENCE TO PHOSPHATE BINDERS

FIGURE 4 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN CALCIUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 5 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 6 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 7 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN IRON-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 8 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN OTHER PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 9 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET SHARE 2018 & 2027 (%)

FIGURE 10 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 11 UNITED KINGDOM HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 12 FRANCE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 13 GERMANY HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 14 SPAIN HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 15 ITALY HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 16 RUSSIA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 17 REST OF EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)


List Of Table

TABLE LIST

TABLE 1 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

TABLE 2 PHOSPHOROUS LEVELS IN SELECT FOODS

TABLE 3 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027 (USD MILLION)

TABLE 4 DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE

TABLE 5 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET COUNTRY ANALYSIS 2019-2027 (USD MILLION)

Licence Rights

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies


Companies

1. JOHNSON AND JOHNSON

2. ZERIA PHARMACEUTICAL

3. AMAG PHARMACEUTICALS

4. SANOFI

5. BRUNO FARMACEUTICI S.P.A.

6. ROCHE DIAGNOSTICS CORPORATION

7. ROYAL DSM N.V.

8. SHIRE

9. CIPLA

10. ULTRAGENYX PHARMACEUTICAL, INC.

11. FERMENTA BIOTECH, LTD.

12. BIOTECH PHARMACAL

13. SUN PHARMACEUTICAL INDUSTRIES, LTD.

14. KERYX BIOPHARMACEUTICALS, INC.

15. FRESENIUS MEDICAL CARE

16. PFIZER, INC.

Company Profile

Company Profile Title

MARKET OUTLOOK

Triton Market Research has estimated the Europe hyperphosphatemia drugs market to show an upward trend in terms of revenue and grow rapidly with a CAGR of 16.11% in the forecasting years 2019-2027.

France, Italy, the United Kingdom, Germany, Russia, Spain and countries in rest of Europe together form the market for hyperphosphatemia drugs in the European region.

The growing aging population and increasing osteoporosis cases in the UK are the major driving factors strengthening the demand for the hyperphosphatemia drugs market in the country. In the UK, around 3 million people are expected to be suffering from osteoporosis. Additionally, more than 230,000 fracture cases are recorded every year due to osteoporosis. A low level of estrogen in women or other hormone might significantly increase the risk of weakening the bones.

The increasing aging population in Spain is considered as the major driving factor to strengthen the demand of the hyperphosphatemia drugs market in the country. Spain accounts for a significant proportion of elderly population within Europe. By 2050, one-fourth of Spain's population is estimated to be over 100 years. The aging population can be considered as the most crucial reason for the rising prevalence of hyperphosphatemia disorders that is driving the growth of the Spain market. In cases of chronic kidney diseases and elderly people, the loss of phosphorus homeostasis due to phosphorus excretion failure causes hyperphosphatemia. And this is growing the demand for the hyperphosphatemia drugs market in the country.

COMPETITIVE OUTLOOK

The companies contending in the market are Fermenta Biotech, Ltd., Sanofi, Roche Diagnostics Corporation, Pfizer, Inc., Royal DSM N.V., Fresenius Medical Care, Sun Pharmaceutical Industries, Ltd., Cipla, AMAG Pharmaceuticals, Keryx Biopharmaceuticals, Inc., Bio-Tech Pharmacal, Ultragenyx Pharmaceutical, Inc., Johnson and Johnson, Shire, Zeria Pharmaceutical and Bruno Farmaceutici S.p.A.

READ MORE

Scope

TABLE OF CONTENT

1. EUROPE HYPERPHOSPHATEMIA DRUGS MARKET-SUMMARY

2. INDUSTRY OUTLOOK

2.1. MARKET DEFINITION

2.2. PORTER'S FIVE FORCE MODEL

2.2.1. THREAT OF NEW ENTRANTS

2.2.2. BARGAINING POWER OF BUYERS

2.2.3. BARGAINING POWER OF SUPPLIERS

2.2.4. THREAT OF SUBSTITUTE PRODUCT

2.2.5. INTENSITY OF COMPETITIVE RIVALRY

2.3. VENDOR SCORECARD

2.4. KEY BUYING OUTLOOK

2.5. KEY INSIGHTS

2.6. KEY MARKET TRENDS

2.7. GUIDELINES RELATED TO THE PHOSPHATE BINDERS

2.8. MARKET DRIVERS

2.8.1. CHRONIC DISORDERS ARE INCREASING RAPIDLY

2.8.2. INCREASE IN PUBLIC COGNIZANCE

2.8.3. INCREASE IN GERIATRIC POPULATION

2.9. MARKET RESTRAINTS

2.9.1. SIDE-EFFECTS RELATED TO THE USAGE OF HYPERPHOSPHATEMIA DRUGS

2.9.2. STRICT FOOD AND DRUG ADMINISTRATION (FDA) REGULATIONS

2.10. MARKET OPPORTUNITIES

2.10.1. RISE IN THE AGING POPULATION

2.11. MARKET CHALLENGES

2.11.1. ALTERNATIVE DIALYSIS TECHNIQUES

2.11.2. ACCESSIBILITY OF DRUGS IS LIMITED

2.11.3. NON-ADHERENCE TO TREATMENT REGIMES

3. HYPERPHOSPHATEMIA DRUGS MARKET OUTLOOK-BY DOSAGES

3.1. SOLID

3.1.1. TABLET

3.1.2. POWDER

3.2. LIQUID

3.2.1. SOLUTION

4. HYPERPHOSPHATEMIA DRUGS MARKET OUTLOOK-BY FORMULATION

4.1.1. CALCIUM-BASED PHOSPHATE BINDERS

4.1.2. ALUMINUM-BASED PHOSPHATE BINDERS

4.1.3. MAGNESIUM-BASED PHOSPHATE BINDERS

4.1.4. IRON-BASED PHOSPHATE BINDERS

4.1.5. OTHER PHOSPHATE BINDERS

5. HYPERPHOSPHATEMIA DRUGS MARKET-REGIONAL OUTLOOK

5.1. EUROPE

5.1.1. COUNTRY ANALYSIS

5.1.1.1. UNITED KINGDOM

5.1.1.2. FRANCE

5.1.1.3. GERMANY

5.1.1.4. SPAIN

5.1.1.5. ITALY

5.1.1.6. RUSSIA

5.1.1.7. REST OF EUROPE

6. COMPETITIVE LANDSCAPE

6.1. JOHNSON AND JOHNSON

6.2. ZERIA PHARMACEUTICAL

6.3. AMAG PHARMACEUTICALS

6.4. SANOFI

6.5. BRUNO FARMACEUTICI S.P.A.

6.6. ROCHE DIAGNOSTICS CORPORATION

6.7. ROYAL DSM N.V.

6.8. SHIRE

6.9. CIPLA

6.10. ULTRAGENYX PHARMACEUTICAL, INC.

6.11. FERMENTA BIOTECH, LTD.

6.12. BIOTECH PHARMACAL

6.13. SUN PHARMACEUTICAL INDUSTRIES, LTD.

6.14. KERYX BIOPHARMACEUTICALS, INC.

6.15. FRESENIUS MEDICAL CARE

6.16. PFIZER, INC.

7. METHODOLOGY & SCOPE

7.1. RESEARCH SCOPE

7.2. SOURCES OF DATA

7.3. RESEARCH METHODOLOGY

 

 

 

 

 

TABLE LIST

TABLE 1 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

TABLE 2 PHOSPHOROUS LEVELS IN SELECT FOODS

TABLE 3 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027 (USD MILLION)

TABLE 4 DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE

TABLE 5 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET COUNTRY ANALYSIS 2019-2027 (USD MILLION)

 

 

 

 

FIGURE LIST

FIGURE 1 PORTER'S FIVE FORCES MODEL OF HYPERPHOSPHATEMIA DRUGS MARKET

FIGURE 2 IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2017

FIGURE 3 RATE OF ADHERENCE TO PHOSPHATE BINDERS

FIGURE 4 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN CALCIUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 5 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 6 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 7 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN IRON-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 8 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN OTHER PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 9 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET SHARE 2018 & 2027 (%)

FIGURE 10 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 11 UNITED KINGDOM HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 12 FRANCE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 13 GERMANY HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 14 SPAIN HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 15 ITALY HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 16 RUSSIA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 17 REST OF EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)


List Of Figure

FIGURE LIST

FIGURE 1 PORTER'S FIVE FORCES MODEL OF HYPERPHOSPHATEMIA DRUGS MARKET

FIGURE 2 IRON-BASED HYPERPHOSPHATEMIA DRUG APPROVAL STATUS 2014-2017

FIGURE 3 RATE OF ADHERENCE TO PHOSPHATE BINDERS

FIGURE 4 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN CALCIUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 5 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN ALUMINUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 6 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN MAGNESIUM-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 7 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN IRON-BASED PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 8 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET IN OTHER PHOSPHATE BINDERS 2019-2027 (USD MILLION)

FIGURE 9 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET SHARE 2018 & 2027 (%)

FIGURE 10 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 11 UNITED KINGDOM HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 12 FRANCE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 13 GERMANY HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 14 SPAIN HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 15 ITALY HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 16 RUSSIA HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

FIGURE 17 REST OF EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)


List Of Table

TABLE LIST

TABLE 1 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET 2019-2027 (USD MILLION)

TABLE 2 PHOSPHOROUS LEVELS IN SELECT FOODS

TABLE 3 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET BY FORMULATION 2019-2027 (USD MILLION)

TABLE 4 DIAGNOSIS AND CLINICAL INDICATORS OF CHRONIC KIDNEY DISEASE

TABLE 5 EUROPE HYPERPHOSPHATEMIA DRUGS MARKET COUNTRY ANALYSIS 2019-2027 (USD MILLION)

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS


Companies

1. JOHNSON AND JOHNSON

2. ZERIA PHARMACEUTICAL

3. AMAG PHARMACEUTICALS

4. SANOFI

5. BRUNO FARMACEUTICI S.P.A.

6. ROCHE DIAGNOSTICS CORPORATION

7. ROYAL DSM N.V.

8. SHIRE

9. CIPLA

10. ULTRAGENYX PHARMACEUTICAL, INC.

11. FERMENTA BIOTECH, LTD.

12. BIOTECH PHARMACAL

13. SUN PHARMACEUTICAL INDUSTRIES, LTD.

14. KERYX BIOPHARMACEUTICALS, INC.

15. FRESENIUS MEDICAL CARE

16. PFIZER, INC.